About this book
Clinical management of bladder cancer is challenging of the heterogeneity among bladder tumors with respect to invasion and metastasis, and frequent occurrence of new tumors in the bladder among patients treated with bladder preservation treatments. Treatment of bladder cancer spans from tumor resection and intravesical treatment, to neoadjuvant chemotherapy, radical surgery and adjuvant chemotherapy. At the same time, bladder cancer is also at the forefront of biomarker development because of the ease of developing noninvasive urine tests. The features of environment-driven carcinogenesis and divergent molecular pathways in the development of low- and high-grade tumors provide a unique opportunity for advance molecular research in cancer biology. Bladder Tumors: Molecular Aspects and Clinical Management is a collection of comprehensive reviews on the state-of-the art basic science research and clinical management of bladder cancer. The book progresses from epidemiology of bladder cancer, molecular basis of bladder carcinogenesis, to standard and molecular aspects of bladder cancer diagnosis and prognosis, and also includes various treatment aspects of both non muscle invasive and muscle invasive bladder cancer. The book features: • Epidemiology, bladder carcinogenesis and divergent molecular pathways of bladder cancer development. • Pathology of bladder tumors, cystoscopy, cytology and newer techniques of bladder cancer diagnosis. • Molecular basis, efficacy and economics of diagnostic and prognostic markers for bladder cancer, with an added feature of recent inventions of molecular nomongrams. • Clinical management of low-grade and non muscle invasive bladder tumors. • Intravesical chemotherapy versus immune (BCG) therapy. • Clinical management of patients with muscle invasive bladder cancer, including neoadjuvant therapy, various aspects of cystectomy including urinary diversion and recent advances such as laproscopic cystectomy • Adjuvant chemotherapy for metastatic bladder cancer and management of upper track tumors • Non-transitional cell carcinoma tumors. The book is truly an international effort to bring the latest development in bladder cancer to the readers. The contributing authors, leaders in their respective areas of expertise-related to bladder cancer, were assembled from different parts of the world. Since the editorial team of the book consists of a translational researcher (Vinata B. Lokeshwar) and practicing urologists with expertise in clinical research (Stefan Hautmann and Axel S. Merseburger), it the Editors’ intent to promote an ongoing dialog among researchers and urologists to help reduce morbidity, mortality associated with bladder cancer, while improving the quality of life for patients.
Bladder Cancer Research Tumors